At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 888 enrolled
Drug / intervention
Mirabegron +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 4, Double-Blind, Randomized, Placebo-Controlled, Parallel Group, Multi-Center Study to Evaluate the Efficacy, Safety, and Tolerability of Mirabegron in Older Adult Subjects With Overactive Bladder (OAB)
In Brief
A Phase 4 clinical trial evaluating Mirabegron and Placebo for Overactive Bladder (OAB). Completed, enrolled 888 participants across 120 sites in 2 countries.
Detailed Summary
The purpose of this study was to assess the efficacy, safety and tolerability of mirabegron versus placebo in the treatment of older adult subjects with OAB.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsOveractive Bladder (OAB)
CountriesCanada, United States
Collaborators--
Timeline
Phase 4CompletedFinished
201520162017201820192020202120222023202420252026
First PostedAug 2014
Enrollment StartOct 2014
Primary CompletionNov 2017
Study CompletionJan 2018
TodayJul 2026
First PostedAug 13, 2014
Enrollment StartOct 7, 2014
Primary CompletionNov 29, 2017
Study CompletionJan 2, 2018
TodayJul 2, 2026
Enrollment to primary: 3.1 yearsPosted 11.9 years ago
Interventions
Mirabegrondrug
oral tablet
Placebodrug
oral tablet